Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

FILE - A Merck scientist conducts research on Feb. 28, 2013, in West Point, Pa. (AP Photo/Matt Rourke, File) (Matt Rourke, Copyright 2017 The Associated Press. All ...

President Donald Trump’s proposed tariffs, while on hold for now, could have sweeping impacts in Pennsylvania and lead to higher prices on goods ranging from appliances to cars to tomatoes. Following ...

Analytical Research & Development, MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States ...

Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a master regulator of mitochondria biogenesis and cell stress playing a role in metabolic and degenerative diseases. In the ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.